We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > PeptiDream

News List

Alnylam and PeptiDream Enter into Collaboration Agreement to Discover and Develop Peptide-siRNA Conjugates for Targeted Delivery of RNAi Therapeutics to a Broader Range of Extrahepatic Tissues firstwordpharma
July 30, 2021
Alnylam Pharmaceuticals, Inc.(Nasdaq: ALNY) announced today a license and collaboration agreement to discover and develop peptide-siRNA conjugates to create multiple opportunities to deliver RNAi therapeutics to tissues outside the liver.
PeptiDream and Merck partner to develop Covid-19 therapeutics pharmaceutical-technology
June 15, 2020
Japanese biopharmaceutical firm PeptiDream has partnered with Merck (MSD) to discover and develop new peptide therapeutics which could neutralise SARS-CoV-2, the novel coronavirus that causes Covid-19.
PeptiDream and Shionogi sign peptide drug conjugate discovery deal pharmaceutical-technology
January 24, 2019
PeptiDream has signed a deal with fellow Japanese pharmaceutical company Shionogi to discover and develop a series of blood-brain barrier (BBB) penetrating peptide drug conjugates.